Hypothesis-Generating Brief: Vitamin D

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Re-curate the source bundle: remove or explicitly demarcate sources where vitamin D is not the primary intervention/exposure (Hontecillas-Prieto 2025, Aquila 2023, Streb 2024, Ramirez-Mejia 2026) or re-classify them as 'mentions vitamin D' rather than as Vitamin D evidence rows. The current 13-source count is inflated by these tangential inclusions.
2. Resolve the inconsistency between reported source statistics (e.g., Zhou 2025 P < 0.05) and the coded direction field (null) by either reporting the direction honestly or removing the statistic where direction cannot be coded.
3. Expand the Tensions and Gaps section to explicitly enumerate at least the named cross-study disagreements (e.g., Middelkoop 2024 vs Fox 2023 on muscle function; Tirgar 2024 vs Romero-Ibarguengoitia 2023 on immune outcomes) rather than only citing the 22-disagreement count.
4. In the Cardiometabolic row of the Findings Map, either remove the Hontecillas-Prieto row or relabel the outcome class to reflect that no actual Vitamin D cardiometabolic intervention evidence is present in the corpus.
5. Justify why several included sources are dated 2025–2026 but the search window is 2026-06-29; verify the publication dates are accurate and note any preprints.

Major issues

• Several sources are misclassified or weakly relevant to a Vitamin D evidence map: Hontecillas-Prieto 2025 is a DLBCL obesity study that only mentions vitamin D as a secondary variable; Aquila 2023 on irisin in postmenopausal women is tangential; Streb 2024 is about VDR expression in breast cancer tissue (observational prognostic, not vitamin D supplementation efficacy); Ramirez-Mejia 2026 is a reanalysis of RNA-seq in Zika-infected macrophages. These dilute the corpus and weaken the claim that 13 sources constitute a meaningful Vitamin D landscape.
• The 'Hontecillas-Prieto 2025' source is coded as 'direction=null' and 'no extracted directional signal' yet is used to label the cardiometabolic outcome class with a claim count (n=1; claims=5). This is a source-class mismatch: obesity/DLBCL prognosis is not a Vitamin D cardiometabolic finding, and the representation inflates apparent coverage of a domain where no actual Vitamin D intervention effect is documented.
• The 'significant source statistic in X/Y sources' reporting repeatedly cites a single p-value (e.g., P < 0.05 in Zhou 2025) without indicating the magnitude, effect size, or confidence interval, and the direction coding is 'null' despite a positive direction being reported in the source excerpt. This creates an internal inconsistency between the reported source statistic and the coded direction field.

Minor issues

• The Tensions and Gaps section is terse (two sentences) and could more explicitly enumerate the 22 cross-study disagreements rather than just citing the count.
• The source-context map (Oncology and cancer, Skeletal and muscle, Aging and geroscience, Infectious-disease and immunology) partly overlaps with the outcome-class map, creating redundant reporting that could be consolidated.
• The Scope statement repeats the '7/13 sources coded null' evidence-honesty note without integrating it into the main Findings Map prose.
• The Fox 2023 excerpt reports a specific effect size (ß = 1.222, 95% CI: 0.377; 2.067) that the manuscript could cite to strengthen the muscle-function direction coding beyond 'mixed'.
• Ramirez-Mejia 2026 is dated 2026, which is plausible for a preprint but should be flagged as such.

Reviewer note

This is an evidence map of Vitamin D across 13 sources and 6 outcome classes. The scope and search summary are auditable, and most findings are attributed to specific cited sources with DOIs that match the bundle entries. The manuscript correctly refuses to collapse into a single efficacy claim, explicitly notes null dominance (7/13 sources coded null), and surfaces a cross-study disagreement count of 22 alongside a named boundary condition (Middelkoop 2024 vs Fox 2023 on muscle function). However, there are material problems. First, the source bundle includes several papers where vitamin D is not the primary intervention: Hontecillas-Prieto 2025 (obesity/DLBCL, vitamin D only as a secondary variable), Aquila 2023 (irisin pilot), Streb 2024 (VDR expression in breast cancer tissue), and Ramirez-Mejia 2026 (Zika macrophage RNA-seq reanalysis). These inflate apparent coverage of outcome classes that the map cannot actually substantiate, particularly the cardiometabolic row, which rests entirely on Hontecillas-Prieto despite the source's null coding and lack of primary vitamin D intervention. Second, there is an internal inconsistency between the reported source-level statistics (e.g., Zhou 2025 P < 0.05) and the direction field (null) — either the direction was extractable and should be coded, or the statistic should not be presented as a directional finding. Third, the Tensions and Gaps section is too compressed relative to the volume of disagreements surfaced. The manuscript's core approach — outcome-class stratification, explicit null coding, and refusal to overclaim — is correct and well-suited to the heterogeneous evidence base. The major issues are curatorial rather than conceptual: with the tangential sources removed or reclassified, the cardiometabolic and contextual-other rows would honestly read as 'no direct Vitamin D evidence', which would actually strengthen rather than weaken the map. As submitted, the bundle overstates coverage and has direction/statistic mismatches that a careful reader will catch. These are bounded but non-trivial fixes, so the recommendation is revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis